The GLP-1 economy in five minutes: verified drug prices, and the business behind them.
Seven days, three clocks.
Everything this brief has been watching converges in the next seven days. Three dates, three calls of ours attached to them, and one of those calls gets graded in public whether it lands or not.
Novo Nordisk’s renamed copies of Ozempic and Wegovy have now sat approved and unsold in Canada for 233 days. In seven days, that number becomes the grade on a call we published in print.
Three clocks are running. This is a short edition about all three, and about what we said would happen on each.
New name, same ledger
You are reading The Downtick. Why the change: our former name lived on a domain we bought fairly and never received. The refund arrived; the lesson stayed.
The Downtick is a name we can own outright, and a downtick, a trade executed at a lower price, is this beat compressed to one word. The record from editions 1 through 6, the dates, and the corrections all stand. Nothing else changes: same beat, same twice-a-week brief, same rule that every number carries a date.
The three clocks
the next seven days, and what we have riding on each
| date | clock | our call on the record |
|---|---|---|
| Mon Aug 17 | Novo v Lilly motion day, decided on the papers | edition 2 had the July 24 filing right |
| Wed Aug 19 | the twins launch window closes | edition 4 called it, edition 6 promised the grade |
| already running | Sevmia, 44 days approved with no price | edition 4 said Novo is waiting for that number |
August 17, five days out
We pulled the docket, so this clock is the one we can describe exactly.
Novo filed its motion for a preliminary injunction on Friday, July 24, three days after filing the underlying suit. It runs to 58 attachments: six declarations, two consumer-survey expert reports, and the disputed commercials themselves entered as evidence. Edition 2 reported the July 24 filing and reported it correctly.
August 17 is not a deadline. It is the motion day, the date the clerk set the fully briefed motion down for decision before Judge Zahid Quraishi. The order says it plainly: decided on the papers, no appearances required.
Briefing is already closed. Lilly filed its opposition on August 10 with seven supporting declarations. Everything the judge is going to read, he has.
Which makes the 17th less of an event than a starting gun. From that date, a ruling can land on any ordinary morning, with no hearing to telegraph it and no notice to anyone. If it comes, the ads either keep running or they stop.
One thing on the record that nobody has reported. Novo’s exhibits include the Zepbound comparative commercial in two versions, marked before revision and after revision. Lilly changed the ad during this fight. The docket does not date the change, and we are going after it.
August 19, seven days out
This is the one with our name on it.
Edition 4 argued that Novo would not launch Plosbrio and Poviztra, its own renamed and lower-priced Ozempic and Wegovy, until after H1 earnings, because no CFO wants to explain a self-cannibalizing launch on results morning. Earnings landed August 5. That put the window at roughly two weeks, closing August 19.
Then edition 6 did the part that costs something: it put the deadline in print and promised the grade publishes either way.
At the deadline the counter reads 240 days. When we checked before sending this, all 17 DINs across the two products (6 for Plosbrio, 11 for Poviztra) still read Approved rather than Marketed in Health Canada’s Drug Product Database, not one of them carries a market date, and no Novo Canada announcement of commercial availability exists.
One caveat we owe you, because it cuts against us. Marketed status in that database depends on the sponsor notifying Health Canada, which is due within 30 days of first sale. A launch inside the last month could in principle not show yet. No pharmacy listing and no announcement supports that scenario, but the caveat is real and it belongs in the grade rather than in the excuse.
So the terms are set. If the 19th passes with 17 DINs still reading Approved, the call was right on the direction and wrong on the clock, and you will read that here with the logic we got wrong laid out. If a DIN flips, you will read that first instead.
Sevmia, already past its window
The third clock has no scheduled date, which is what makes it the interesting one.
Sevmia, Apotex’s generic Wegovy and the first one approved in Canada for chronic weight management, was approved on June 29. That is 44 days ago. It becomes 51 on the 19th.
The window came from a precedent, not a vibe. Ozempic-label generics approved in late April and on May 1 were dispensing within weeks, and Apotex shipped one of them itself, which is why the stocking estimate for Sevmia read late July to August. Six weeks in, that estimate is spent.
Our read, held loosely: pens are the constraint. Injectable generics are easy to approve and hard to manufacture at volume, and Hypera said exactly that about Brazil. What we do not believe is that Apotex forgot.
Meanwhile the field grew while nobody was looking. Aspen Pharmacare’s generic semaglutide was approved July 17, a fourth manufacturer, unlaunched, and as far as we can find, unreported anywhere until now. We found it in the government database. That is the whole method.
Now the part where we correct ourselves, because we also pulled the pricing framework today and it does not say what we have been implying.
The pan-Canadian Tiered Pricing Framework sets generic prices as percentages of the brand reference price, and it counts competitors inside a category defined by which brand the generic copies. One competitor, 85% of brand, or 75% falling to 55% after three months where the brand had a listing agreement. Two competitors, 50%. Three or more, 25% if the product is an oral solid and 35% if it is anything else.
Semaglutide comes in pens, so the floor is 35%, not 25%. Every line you have read about Canadian generics falling to a quarter of the brand price was written about pills.
And the category rule moves Sevmia out of the story we put it in. Sevmia copies Wegovy, and no generic Wegovy is on the Canadian market, so Sevmia would not be a third anything. It would be a first, in a category of its own, at 85% or at 75%. The third-competitor step belongs to the Ozempic-label category, where Dr Reddy’s and Apotex are already selling and Aspen is the one waiting.
So the number we have been calling the third-generic trigger was the right arithmetic on the wrong unit. There is a live question left, and it is a better one: the framework only governs prices where a public plan reimburses the brand, and no provincial plan covers Wegovy for weight. If that holds, these tiers may not touch Sevmia’s price at all. We are asking the alliance directly. When we know, you will.
What has not moved while all of this settles: the off-label route stays where it has been all year, $88 to $120 a month at pharmacies, $88 to $99 at Costco, $149 all-in through telehealth.
The board going in
Four things we have already reported that these seven days land on top of. Three of the four link the same edition, because three days ago was most of the story. That is what this stretch has been.
Guidance raised twice, and the stock fell anyway. On August 5 Novo raised full-year guidance for the second time in six months, to 0 to minus 6% from minus 4 to minus 12, on a quarter up 3% at constant currency and 7% adjusted. Shares closed down 5%. The market has stopped grading Novo on volume and started grading it on price. That was edition 6.
The erosion ledger. Underneath the raise: US injectable Wegovy sales down 22% on lower realized prices, Ozempic’s US pricing eroding 10 to 15% a year per the CFO, adjusted gross margin at 78.2% from 82.7%, headcount down 15%. Lilly’s own release concedes lower realized prices on both of its flagships too, so this is the category’s condition and not one company’s. The thesis is older than the numbers: edition 1 wrote that volume can grow while revenue falls, and that this is what a commodity looks like being born.
The pill scoreboard. Novo’s Wegovy pill is running above 265,000 US prescriptions a week and past 5 million since January, and it still came in under consensus for the quarter at DKK 3.22 billion against 3.27 expected. Lilly’s Foundayo booked $98 million in its first full quarter, below forecasts, against roughly $500 million equivalent for Novo’s pill. The 9 to 1 script gap now has a 5 to 1 revenue confirmation. Also edition 6.
Brazil’s queue. Novo’s own second-half caution names semaglutide patent expiries in Canada and Brazil. The Brazilian patent fell in March, the Superior Court of Justice unanimously refused to extend it, and five companies are now queuing generics, Hypera plus four seeking approval. The patent collapse is multi-country in the company’s own framing, which is the part worth keeping. Edition 6 again.
Watching for
- August 17, Monday: motion day in Novo v Lilly. Briefing is closed, so a ruling can arrive any morning from then, on the papers, without a hearing.
- August 19, Wednesday: the twins deadline. 240 days approved. The grade publishes either way.
- Sevmia’s price, day 44 and counting. And whether the pricing framework governs it at all, given that no public plan reimburses the brand it copies.
That is the brief. Same time Sunday.
Updated August 12, 2026: two corrections, both from primary sources we pulled the same day this published. First, the docket: Novo filed its preliminary-injunction motion on July 24, and August 17 is the motion day on which the fully briefed motion goes to the judge on the papers, not a filing deadline. An earlier version treated the date as a possible filing deadline and doubted our own July 24 reporting. Our reporting was right; the secondhand summary was not. Second, the pricing framework: we pulled the pan-Canadian Tiered Pricing Framework itself. The tiers are percentages of the brand reference price, 85% or 75-falling-to-55% at one competitor, 50% at two, and 35% at three or more for injectables (25% applies only to oral solids), counted per brand reference category. The dollar caps we printed as “reportedly ~$114 and ~$80” were those percentages wearing the wrong label, and the “third generic” framing was the wrong unit: Sevmia would be the first generic in its own Wegovy-reference category, and Aspen is the candidate third in the Ozempic-reference category. Whether the framework governs Sevmia’s price at all turns on a reimbursement-eligibility question we have not yet settled, and that is now the watch item.